Brief: Kyverna Therapeutics Announces Positive Interim Phase 2 Data From KYSA-6 Study Of KYV-101 In Generalized Myasthenia Gravis At AANEM 2025
29/10/2025 10:31
Oct 29 (Reuters) - Kyverna Therapeutics Inc KYTX.O: KYVERNA THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 2 DATA FROM KYSA-6 STUDY OF KYV-101 IN GENERALIZED MYASTHENIA GRAVIS AT AANEM 2025 KYVERNA THERAPEUTICS INC - KYV-101 WELL-TOLERATED WITH NO HIGH-GRADE CRS OR ICANS OBSERVED Source text: ID:nGNX7WRQ8D Further company coverage: KYTX.O
Recent news on Kyverna Therapeutics
See all newsHealth Rounds: Appendix removal linked with lower colon cancer risk in study
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants